Show simple item record

dc.contributor.authorArtzy-Schnirman, Arbel
dc.contributor.authorHobi, Nina
dc.contributor.authorSchneider-Daum, Nicole
dc.contributor.authorGuenat, Olivier T
dc.contributor.authorLehr, Claus-Michael
dc.contributor.authorSznitman, Josué
dc.date.accessioned2019-09-13T12:49:46Z
dc.date.available2019-09-13T12:49:46Z
dc.date.issued2019-09-06
dc.identifier.citationEur J Pharm Biopharm. 2019 Sep 6. pii: S0939-6411(19)30785-4. doi: 10.1016/j.ejpb.2019.09.006.en_US
dc.identifier.issn1873-3441
dc.identifier.pmid31499161
dc.identifier.doi10.1016/j.ejpb.2019.09.006
dc.identifier.urihttp://hdl.handle.net/10033/621936
dc.description.abstractWith rapid advances in micro-fabrication processes and the availability of biologically-relevant lung cells, the development of lung-on-chip platforms is offering novel avenues for more realistic inhalation assays in pharmaceutical research, and thereby an opportunity to depart from traditional in vitro lung assays. As advanced models capturing the cellular pulmonary make-up at an air-liquid interface (ALI), lung-on-chips emulate both morphological features and biological functionality of the airway barrier with the ability to integrate respiratory breathing motions and ensuing tissue strains. Such in vitro systems allow importantly to mimic more realistic physiological respiratory flow conditions, with the opportunity to integrate physically-relevant transport determinants of aerosol inhalation therapy, i.e. recapitulating the pathway from airborne flight to deposition on the airway lumen. In this short opinion, we discuss such points and describe how these attributes are paving new avenues for exploring improved drug carrier designs (e.g. shape, size, etc.) and targeting strategies (e.g. conductive vs. respiratory regions) amongst other. We argue that while technical challenges still lie along the way in rendering in vitro lung-on-chip platforms more widespread across the general pharmaceutical research community, significant momentum is steadily underway in accelerating the prospect of establishing these as in vitro "gold standards"en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/ 677772en_US
dc.rightsembargoedAccessen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectaerosolsen_US
dc.subjectcellular airway barrieren_US
dc.subjectinhalation assaysen_US
dc.subjectmicrofluidicsen_US
dc.subjectorgan-on-chipen_US
dc.titleAdvanced in vitro lung-on-chip platforms for inhalation assays: From prospect to pipeline.en_US
dc.typeArticleen_US
dc.contributor.departmentHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
dc.identifier.journalEuropean Journal of Pharmaceutics and Biopharmaceuticsen_US
refterms.dateFOA2019-09-06T00:00:00Z
dc.source.journaltitleEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
ArtzySchnirman et al.pdf
Size:
6.289Mb
Format:
PDF
Description:
original manuscript

This item appears in the following Collection(s)

Show simple item record

embargoedAccess
Except where otherwise noted, this item's license is described as embargoedAccess